OHSU Brain Institute Newsletter

Breakthrough Treatments

Breakthrough Treatments

Successfully treating previously inoperable aneurysms. The FDA-approved Pipeline™ Embolization Device (PED) is a breakthrough treatment for patients with previously inoperable aneurysms. A longtime leader in advanced endovascular care, OHSU is the only place in Oregon FDA-certified to use PED. Read more

translational medicine

Translational Medicine

Korlym studied in treating Cushing's Syndrome. OHSU was the largest enroller during a multicenter, open-label phase 3 trial to evaluate the safety and efficacy of Korlym (mifepristone), in endogenous Cushing's Syndrome (CS). We provide all-inclusive expert care for difficult-to-treat pituitary and adrenal diseases. Read more

advancing research

Advancing Research

Currently enrolling for studies of acute ischemic stroke treatment. While neuroprotective agents are still being investigated for acute ischemic stroke treatment, research taking place at OHSU is leading to new knowledge. Several neuroprotectant clinical trials are currently ongoing, and we are seeking new patients. Read more

complex case conference: epilepsy

Complex Case Conference Epilepsy

Multidisciplinary teams treat epilepsy patients. At OHSU, epilepsy specialists in multiple disciplines meet monthly to review patient cases and treatments. Patients with complex medically refractory epilepsy may benefit from surgery to reduce or eliminate seizures. Read more

indications for spine referral

Indications for Spine Referral

Patient-centered therapies and symptom managementbenefit spine patients. Spinal surgery can be a daunting proposition for patients. At the OHSU Spine Center, we focus on patient-centered therapies and symptom management for degenerative spine conditions well before considering surgery. Read more